At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Pre-Mkt 06-12 04:13:20 EDT
6.50
-0.08
-1.22%
盘前6.49
-0.01-0.15%
04:06 EDT
High6.71Low6.29Vol973.04K
Open6.59D1 Closing6.58Amplitude6.46%
Mkt Cap203.38MTradable Cap102.00MTotal Shares31.29M
T/O6.29MT/O Rate6.20%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Allergy Therapeutics Highlights Positive Allergy Trial Data at EAACI 2026
TIPRANKS  ·  14:09
Allergy Therapeutics Highlights Positive Allergy Trial Data at EAACI 2026
Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment
MT Newswires Live  ·  08:05
Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment
Quince Therapeutics Stockholders Approve Reverse Split Authorization
TIPRANKS  ·  06:42
Quince Therapeutics Stockholders Approve Reverse Split Authorization
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
TIPRANKS  ·  05:05
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
TIPRANKS  ·  02:05
Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  00:18
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity
Adial Pharmaceuticals announces acquisition of Azora Therapeutics
TIPRANKS  ·  06-11 23:50
Adial Pharmaceuticals announces acquisition of Azora Therapeutics
Viking Therapeutics Appoints Dr. Hubert C. Chen as New Chief Medical Officer
Deep News  ·  06-11 23:10
Viking Therapeutics Appoints Dr. Hubert C. Chen as New Chief Medical Officer
Kazia Therapeutics Initiated at Buy by Lake Street
Dow Jones  ·  06-11 23:02
Kazia Therapeutics Initiated at Buy by Lake Street
Silence Therapeutics Unveils Extended Divesiran Follow-Up Data Demonstrating Sustained Efficacy and Best-in-Class Potential
Deep News  ·  06-11 22:30
Silence Therapeutics Unveils Extended Divesiran Follow-Up Data Demonstrating Sustained Efficacy and Best-in-Class Potential
Summit Therapeutics Withdraws Public Offering Due to Market Conditions
MT Newswires Live  ·  06-11 21:57
Summit Therapeutics Withdraws Public Offering Due to Market Conditions
Summit Therapeutics withdraws proposed underwritten public offering
TIPRANKS  ·  06-11 21:50
Summit Therapeutics withdraws proposed underwritten public offering
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
MT Newswires Live  ·  06-11 21:11
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
Atossa Therapeutics Announces Registered Direct Offering and Warrants
TIPRANKS  ·  06-11 20:41
Atossa Therapeutics Announces Registered Direct Offering and Warrants
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering
MT Newswires Live  ·  06-11 20:39
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering
Lake Street Initiates Coverage on Kazia Therapeutics With Buy Rating, $32 Price Target
MT Newswires Live  ·  06-11 20:38
Lake Street Initiates Coverage on Kazia Therapeutics With Buy Rating, $32 Price Target
Kazia Therapeutics initiated with a Buy at Lake Street
TIPRANKS  ·  06-11 19:46
Kazia Therapeutics initiated with a Buy at Lake Street
Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Dow Jones  ·  06-11 19:00
Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Faeth Therapeutics Rebranding and PIKTOR Pipeline Catalysts Support High-Risk Buy, $55 Price Target Reiterated
TIPRANKS  ·  06-11 18:55
Faeth Therapeutics Rebranding and PIKTOR Pipeline Catalysts Support High-Risk Buy, $55 Price Target Reiterated
HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target
MT Newswires Live  ·  06-11 18:39
HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--